Relationship between thymus output function in CML patients and their bcr-abl mRNA levels.
- Author:
Su-Xia GENG
1
;
Xin DU
;
Jian-Yu WENG
;
Shao-Hua CHEN
;
Li-Jian YANG
;
Yang-Qiu LI
Author Information
1. Department of Hemotology, Guangdong Provincial People Hospital, Guangzhou 510080, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Female;
Fusion Proteins, bcr-abl;
biosynthesis;
genetics;
Gene Rearrangement;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
immunology;
Male;
Middle Aged;
Proto-Oncogene Proteins c-abl;
biosynthesis;
genetics;
Proto-Oncogene Proteins c-bcr;
biosynthesis;
genetics;
RNA, Messenger;
biosynthesis;
genetics;
Receptors, Antigen, T-Cell;
analysis;
immunology;
T-Lymphocytes;
chemistry;
immunology;
Thymus Gland;
immunology
- From:
Journal of Experimental Hematology
2007;15(1):138-141
- CountryChina
- Language:Chinese
-
Abstract:
The study was purposed to analyze the relationship between the content of T-cell receptor excision DNA circles (TREC) and bcr-abl mRNA levels in CML patients and to evaluate the prognostic significance of recent thymic output function detection in patients with chronic myelogenous leukemia (CML). Quantitative detection of TREC and bcr-abl fusion gene transcripts in peripheral blood from 15 CML patients were preformed by real-time PCR. The change of bcr-abl levels in 6 patients was followed-up for two years. The results showed that there was no significant correlation between TREC and bcr-abl mRNA levels in peripheral blood from CML patients for the first attack. Patients who had higher TREC at diagnosis had a larger reduction of bcr-abl after 2 years of follow-up. While out of 2 patients who underwent haemopoietic stem cell transplantation (HSCT), one patient with higher level of TREC before transplantation was confirmed to express undetectable level of TREC by three consecutive detections after transplantation, other one patient was identified to express low level of bcr-abl. It is concluded that high thymic output function in CML patients can be beneficial for killing the residual CML cells.
